Variant Angina is Associated with Myocarditis
Xin Xu,James Jiqi Wang,Hu Zhao,Kun Miao,Guanglin Cui,Yuxuan Zhang,Xiaoyun Yang,Luyun Wang,Junfang Wu,Dao Wen Wang
DOI: https://doi.org/10.2147/jir.s378152
IF: 4.5
2022-08-30
Journal of Inflammation Research
Abstract:Xin Xu, 1, 2, &ast James Jiqi Wang, 1, 2, &ast Hu Zhao, 1, 2 Kun Miao, 1, 2 Guanglin Cui, 1, 2 Yuxuan Zhang, 1, 2 Xiaoyun Yang, 1, 2 Luyun Wang, 1, 2 Junfang Wu, 2 Dao Wen Wang 1, 2 1 Division of Cardiology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China; 2 Hubei Key Laboratory of Genetics and Molecular Mechanism of Cardiological Disorders, Wuhan, People's Republic of China &astThese authors contributed equally to this work Correspondence: Dao Wen Wang; Junfang Wu, Division of Cardiology, Department of Internal Medicine Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1095# Jiefang Ave, Wuhan, 430030, People's Republic of China, Tel/Fax +86-278366-3280, Email ; Background: Vasospastic angina (VSA) is caused by severe diffuse or segmental coronary artery spasms. Patients with variant angina have poor clinical outcomes, although nitrates and calcium blockers help improve patient symptoms because there is no understanding of the etiology and causal treatment. The present study investigated whether VSA is associated with inflammation of the heart. Patients and Methods: A total of 109 patients with VSA diagnosed by the presence of recurrent angina pectoris, typical electrocardiography, and coronary angiography were recruited, and 61 normal participants and 61 patients with acute myocardial infarction (AMI) and coronary artery stenosis were recruited as controls. The plasma levels of 24 cytokines were measured using a magnetic Luminex assay, and endothelin-1 and histamine levels tested using enzyme-linked immunosorbent assay and mass-spectrometry, respectively, for all participants. Furthermore, four patients with VSA underwent 18-fluorine fluorodeoxyglucose ( 18 F-FDG) positron emission tomography/computed tomography (PET/CT). Results: The plasma levels of interleukin (IL)-12p70, IL-13, PDL-1, IL-10, IL-6, IL-15, macrophage inflammatory protein (MIP)-1α, and MIP-1β in patients with VSA were significantly higher than those in both normal controls and patients with AMI (p< 0.001) but did not differ between normal controls and patients with AMI. 18 F-FDG PET/CT showed that the left ventricle, coronary perivascular tissue volume, and coronary perivascular FDG uptake were significantly increased in all four patients. Conclusion: Our findings demonstrate that VSA patients have significantly elevated plasma cytokine levels and myocardial and pericoronary inflammation, suggesting that VSA is associated with myocarditis. This study provides novel insights into the etiology and treatment of VSA. Keywords: variant angina, myocarditis, cytokines, inflammation Vasospastic angina (VSA), formerly known as variant angina or Prinzmetal angina, is mainly caused by transient narrowing due to vasoconstriction of the coronary artery, leading to clinical symptoms that present as chest pain and are usually accompanied by ST-segment elevation or ST-segment depression on the ECG. 1 It is classified as a focal or diffuse coronary artery spasm (CAS). Clinically, severe vasospastic angina causing total coronary occlusion can induce a wide range of myocardial infarctions and is life-threatening. 2 It was reported that the prevalence rate of VSA ranged from 33.4% to 57.6% in western countries and 40% to 79% in Asian countries. Importantly, patients with VSA have relatively poor clinical outcomes, even if current therapies with calcium channel blockers and nitrates can effectively relax spastic coronary arteries and improve angina symptoms in these patients. 3 The exact etiology of VSA remains unknown, and spastic coronary artery segments have no stenosis in most patients. Therefore, VSA may differ from atherosclerotic lesions. Furthermore, statins have been used worldwide to reduce adverse events in patients with coronary artery disease (CAD), and antiplatelet therapy using aspirin or aspirin plus clopidogrel is used for the primary and secondary prevention of CAD. However, the application of these treatments has not reduced adverse events as expected in patients with VSA. 4,5 These studies suggest that hypercholesterolemia and platelet activation are not pathogenic factors of VSA. An early study found that platelet-activating factor (PAF) can induce coronary spasm, inflammatory cell-derived interleukin 1 (IL-1) is a potent inducer of PAF, 6,7 and mast- -and eosinophil-released histamine (HA) i -Abstract Truncated-
immunology